SIEGALL CLAY B 4

What Happened

• Clay B. Siegall, President, CEO and a director of Immunome Inc. (IMNM), made a purchase (Form 4 code: P) of 25,450 shares on 2026-03-27. The weighted average price was $19.67, for a total reported cost of $500,602. The filing lists the transaction as an open-market or private purchase.

Key Details

• Transaction date: 2026-03-27
• Price: weighted average $19.67; price range reported between $19.63 and $19.70 (see footnote)
• Shares acquired: 25,450; Total value: $500,602
• Transaction code: P (Purchase)
• Shares owned after the transaction: not specified in the provided filing
• Filing timeliness: Form 4 was filed 2026-03-31, which appears to be within the required two business days (timely)
• Footnote: Issuer notes the weighted average and that the exact number of shares purchased at each price between $19.63–$19.70 will be provided upon request by SEC staff, the issuer, or any security holder

Context

• This is a direct purchase by the CEO, which many investors view as a stronger signal than routine sales because it increases insider exposure to company stock; the filing does not state any plan (e.g., 10b5-1) or other non-standard circumstances. No options exercise, gift, or tax-withholding transactions were reported in this filing.